Thailanstatin A is a potent natural product isolated from Burkholderia thailandensis MSMB43. It functions as an ultra-potent inhibitor of eukaryotic RNA splicing by binding to the SF3b subunit of the U2 snRNA subcomplex of the spliceosome. This mechanism results in low-nanomolar to sub-nanomolar IC50 values across various human cancer cell lines, including DU-145, NCI-H232A, MDA-MB-231, and SKOV-3. Due to its high potency and specificity, Thailanstatin A is being explored as a payload for antibody-drug conjugates (ADCs), offering a promising avenue for targeted cancer therapy.
Thailanstatin A's selective inhibition of RNA splicing in cancer cells makes it a valuable candidate for targeted cancer therapies. Its potential use in ADCs allows for precise delivery of cytotoxic agents to tumor cells, minimizing damage to healthy tissues and reducing side effects. This specificity enhances the therapeutic index of cancer treatments, offering improved outcomes for patients with various malignancies.